Ionis Pharmaceuticals Files 8-K Report
Ticker: IONS · Form: 8-K · Filed: Apr 8, 2024 · CIK: 874015
Sentiment: neutral
Topics: 8-K, financial-reporting
TL;DR
IONIS filed an 8-K, mostly financial docs, no major news.
AI Summary
On April 7, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates routine administrative or financial reporting by Ionis Pharmaceuticals, Inc. to the SEC.
Risk Assessment
Risk Level: low — The filing appears to be routine administrative or financial reporting without any disclosed material events.
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Filer
- 2855 GAZELLE COURT (location) — Principal Executive Offices Address
- CARLSBAD (location) — City of Principal Executive Offices
- CA (location) — State of Principal Executive Offices
- 92010 (location) — Zip Code of Principal Executive Offices
- 7609319200 (phone_number) — Business Phone Number
- ISIS PHARMACEUTICALS INC (company) — Former Company Name
- 19930328 (date) — Date of Name Change
- April 7, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for reporting financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 7, 2024.
What is the principal executive office address for Ionis Pharmaceuticals, Inc.?
The principal executive office address is 2855 Gazelle Court, Carlsbad, CA 92010.
What was the former name of Ionis Pharmaceuticals, Inc.?
The former name of Ionis Pharmaceuticals, Inc. was ISIS PHARMACEUTICALS INC.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.1 · Accepted 2024-04-08 06:04:00
Filing Documents
- ef20026226_8k.htm (8-K) — 26KB
- ef20026226_ex99-1.htm (EX-99.1) — 33KB
- 0001140361-24-018449.txt ( ) — 198KB
- ions-20240407.xsd (EX-101.SCH) — 4KB
- ions-20240407_lab.xml (EX-101.LAB) — 21KB
- ions-20240407_pre.xml (EX-101.PRE) — 16KB
- ef20026226_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On April 7, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing positive results from the Phase 3 Balance study of olezarsen for the treatment of adults with familial chylomicronemia syndrome (FCS). A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: April 8, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel